Advertisement
A trader reacts as he works on the trading floor of the stock exchange in Hong Kong on February 3, 2016. Hong Kong stocks plunged in the morning session on February 3 as another sell-off in oil hammered energy firms, while insurance companies were also hit by a report China would clamp down on the purchase of overseas cover. AFP PHOTO / ANTHONY WALLACE

Ginseng is a good energizer but an overdose will cause bleeding, so the folks say. Hang Fat Ginseng has certainly lived up to its name.

Advertisement

Its profit and share price tripled from late 2015 onwards. Then, on January 28, its price dived 91 per cent within the first 15 minutes of trading.

Yesterday, its founder and Chairman Matthew Yeung said he’s selling his control to pay off some margin financing. His financier is likely to take control of the listed shell which worth HK$600 million, according to market sources.

This is a classic tale of what has and would happen to the dozens of newly listed companies in the past two years. It is a tale of greed.

Yeung is no stranger to the game.

Advertisement

The so-called “King of American Ginseng” loved to talk about his clever bets on apartments, currencies as well as derivatives.

Advertisement